Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Ocular Therapeutix (OCUL) Cost of Revenue: 2013-2025

Historic Cost of Revenue for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $13.1 million.

  • Ocular Therapeutix's Cost of Revenue rose 23.79% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.8 million, marking a year-over-year increase of 29.53%. This contributed to the annual value of $41.6 million for FY2024, which is 2.57% up from last year.
  • Ocular Therapeutix's Cost of Revenue amounted to $13.1 million in Q3 2025, which was down 4.67% from $13.7 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Cost of Revenue peaked at $14.1 million during Q1 2025, and registered a low of $8.1 million during Q1 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $10.8 million (2023), whereas its average is $11.2 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first spiked by 46.87% in 2021, then fell by 12.22% in 2023.
  • Quarterly analysis of 5 years shows Ocular Therapeutix's Cost of Revenue stood at $9.1 million in 2021, then climbed by 15.28% to $10.5 million in 2022, then fell by 12.22% to $9.2 million in 2023, then rose by 17.25% to $10.8 million in 2024, then rose by 23.79% to $13.1 million in 2025.
  • Its Cost of Revenue stands at $13.1 million for Q3 2025, versus $13.7 million for Q2 2025 and $14.1 million for Q1 2025.